Last reviewed · How we verify
ADC-1013
At a glance
| Generic name | ADC-1013 |
|---|---|
| Sponsor | Alligator Bioscience AB |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers (PHASE2, PHASE3)
- Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients (PHASE1, PHASE2)
- A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors (PHASE1)
- ADC-1013 First-in-Human Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |